Appointments at BiPar Sciences
This article was originally published in Scrip
BiPar Sciences, a private US biopharmaceutical company developing PARP inhibitors as cancer therapies, has appointed Sunil Patel vice-president of corporate development and marketing, and Adrienne Weil legal counsel. Mr Patel previously served as vice-president of corporate development at Allos Therapeutics, while Ms Weil formerly worked at the law offices of Orrick, Herrington & Sutcliffe.
You may also be interested in...
October and November 2020 were bad months for companies seeking to have their planned EU filings fast-tracked through the centralized drug review system at the European Medicines Agency.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.